"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Precautions normally associated with anterior segment surgical procedures should be observed.
Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should be carefully monitored and appropriate therapy instituted if significant increases occur.
PROVISC (sodium hyaluronate) material is obtained from microbial fermentation by a purified proprietary process. Although precautions have been taken to make this device protein-free and it has been tested in animals for allergenic response, this device, used in susceptible persons, may produce allergenic responses.
This product contains dry natural rubber (latex).
In addition to the above, the following precautions should be observed:
-Do not reuse cannulas.
-Use only if material is clear.
-Avoid trapping air bubble.
Last reviewed on RxList: 2/15/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Provisc Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.